Literature DB >> 30832999

Cytokine Therapy.

Ann W Silk1, Kim Margolin2.   

Abstract

The processes controlled by cytokines may be co-opted by pathologic states, contributing to processes that threaten host well-being. A nuanced understanding of this immense web of chemical communications will allow us to understand the mechanisms and limitations of current therapies and to enhance their therapeutic benefits while minimizing their toxicities. This article reviews the current state of cytokine science in malignancy, focusing on agents that are approved for therapy or are in late-stage development. Promising new directions, including novel engineered.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytokine; Interferon; Interleukin; Melanoma; Renal cell carcinoma

Mesh:

Substances:

Year:  2019        PMID: 30832999     DOI: 10.1016/j.hoc.2018.12.004

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  6 in total

1.  Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?

Authors:  Matthew Zibelman; Elizabeth R Plimack
Journal:  Ann Transl Med       Date:  2019-07

2.  The predictive prognostic values of serum interleukin-2, interleukin-6, interleukin-8, tumor necrosis factor-α, and procalcitonin in surgical intensive care unit patients.

Authors:  Yamin Yan; Yan Hu; Xiaorong Wang; Zhenghong Yu; Yingjia Tang; Yuxia Zhang; Wenyan Pan
Journal:  Ann Transl Med       Date:  2021-01

3.  Variable roles of interleukin-17F in different cancers.

Authors:  Tiina Mikkola; Rabeia Almahmoudi; Tuula Salo; Ahmed Al-Samadi
Journal:  BMC Cancer       Date:  2022-01-11       Impact factor: 4.430

Review 4.  Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.

Authors:  Siting Yu; Yang Wang; Ping He; Bianfei Shao; Fang Liu; Zhongzheng Xiang; Tian Yang; Yuanyuan Zeng; Tao He; Jiachun Ma; Xiran Wang; Lei Liu
Journal:  Front Oncol       Date:  2022-02-07       Impact factor: 6.244

5.  Clinically translatable cytokine delivery platform for eradication of intraperitoneal tumors.

Authors:  Amanda M Nash; Maria I Jarvis; Samira Aghlara-Fotovat; Sudip Mukherjee; Andrea Hernandez; Andrew D Hecht; Peter D Rios; Sofia Ghani; Ira Joshi; Douglas Isa; Yufei Cui; Shirin Nouraein; Jared Z Lee; Chunyu Xu; David Y Zhang; Rahul A Sheth; Weiyi Peng; Jose Oberholzer; Oleg A Igoshin; Amir A Jazaeri; Omid Veiseh
Journal:  Sci Adv       Date:  2022-03-02       Impact factor: 14.136

Review 6.  Shaping Immune Responses in the Tumor Microenvironment of Ovarian Cancer.

Authors:  Xin Luo; Jing Xu; Jianhua Yu; Ping Yi
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.